| |

The Peritoneal Cancer Index in Mesothelioma Prognosis

peritoneal cancer index

The peritoneal cancer index is a valuable prognostic tool and should be considered in mesothelioma treatment planning.

That is the word from a group of Finnish cancer researchers. They analyzed twelve years of data on peritoneal mesothelioma in their country.

Mesothelioma patients with a higher peritoneal cancer index had a worse prognosis than those with a lower PCI. The group says cancer doctors ought to be including the PCI in their decision-making for people with peritoneal mesothelioma.

What is the Peritoneal Cancer Index?

Peritoneal mesothelioma makes up about a fifth of all mesothelioma cases. It grows on the peritoneum, a membrane that surrounds the abdominal organs. As cancer spreads, tumors can show up in other areas inside the peritoneal cavity. 

The Peritoneal Cancer Index or PCI is a way for doctors to measure how widespread these tumors are. The more confined a patient’s mesothelioma is, the lower their PCI score.

To estimate a patient’s PCI, doctors imagine that the peritoneal cavity has thirteen different regions. Using MRI and/or CT scans, they measure the size of the largest tumor in each of the 13 regions. They use those numbers to come up with a peritoneal cancer index score. 

Doctors can use the PCI to plan for surgery and other mesothelioma treatments. PCI can help determine if a mesothelioma patient is a candidate for CRS surgery with HIPEC.

The PCI and Mesothelioma Prognosis

Researchers with the University of Eastern Finland and Helsinki University directed the new analysis. It included all Finnish peritoneal mesothelioma patients diagnosed between 2000 and 2012. 

The team gathered additional clinical and outcome data from the Finnish Cancer Registry, the Workers’ Compensations Center, and Statistics Finland. A radiologist examined the CT and MRI data for each patient to determine their peritoneal cancer index score. 

The median PCI score was 25. The team determined that mesothelioma patients with a peritoneal cancer index of 19 or lower had the best outcomes and survived the longest. Those with a PCI equal to or higher than 30 had the shortest survival. 

“Our study indicates that radiological PCI is prognostic in malignant peritoneal mesothelioma and should be assessed during radiographic workup and integrated into clinical decision-making,” writes lead author Silja Salo of the Institute of Clinical Medicine at the University of Eastern Finland.

An American study earlier this year found MRI was better than CT for determining PCI in peritoneal mesothelioma patients. 

That study included nearly 500 patients. It showed that doctors were more likely to be able to remove all traces of cancer in patients with a PCI below 15.

Source:

Salo, SAS, et al, “Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study”, August 6, 2020, Scientific Reports, https://www.nature.com/articles/s41598-020-70044-8

Lee, RM, et al, “What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative”, December 12, 2019, https://www.clinical-colorectal-cancer.com/article/S1533-0028(19)30483-9/fulltext

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…

  • | |

    Mesothelioma Study Finds New Treatment Target

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…

  • | |

    Could Statin Drugs Help Fight Mesothelioma?

    A new study suggests that some of the most popular drugs used to treat high cholesterol may also help combat deadly malignant mesothelioma. That finding comes from Japanese research, published recently in the medical journal, Cancer Letters. The study found a “synergistic effect” in mesothelioma cells between two statin drugs, atorvastatin (Lipitor) and simvastatin (Zocor) and gamma tocotrienol (y-T3), a form of Vitamin E. “Statin+y-T3 combinations induced greater cell growth inhibition more than each single treatment,” write the authors in the summary of their findings. The combination of statin drugs and gamma-tocotrienol appears to work by inhibiting an important metabolic pathway inside the mesothelioma cells, making it impossible for them to synthesize or utilize certain critical molecules. When the researchers…